Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
The participating investors were the existing shareholder Invus, as well as one or more funds under the management of Capital Group, a new investor in Vicore.
Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's shares are listed on Nasdaq Stockholm.
Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.
